<DOC>
	<DOCNO>NCT03051217</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety Certolizumab Pegol ( CZP ) treatment moderate severe chronic plaque Psoriasis ( PSO ) Japanese subject .</brief_summary>
	<brief_title>A Study Test Efficacy Safety Certolizumab Pegol Japanese Subjects With Moderate Severe Chronic Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject male female , &gt; = 20 year age . Institutional Review Boardapproved write informed consent form sign dated subject . Other protocoldefined inclusion criterion may apply . For subject moderate severe chronic plaque psoriasis ( PSO ) Chronic plaque psoriasis least 6 month . Baseline Psoriasis Activity Severity Index ( PASI ) &gt; =12 Body Surface Area ( BSA ) affect PSO &gt; =10 % Physician 's Global Assessment ( PGA ) score 3 high . Candidates systemic PSO therapy and/or phototherapy and/or chemophototherapy . For subject generalize pustular PSO erythrodermic PSO Diagnosis generalize pustular PSO erythrodermic PSO Screening . History plaquetype PSO subject diagnosis erythrodermic PSO . Baseline BSA affect PSO &gt; =80 % subject diagnosis erythrodermic PSO . Female subject breastfeeding , pregnant , plan become pregnant study within 5 month follow last dose study drug . Male subject planning partner pregnancy study within 5 month follow last dose study drug . Subject guttate psoriasis druginduced psoriasis . For subject moderate severe plaque psoriasis , erythrodermic pustular form psoriasis also exclude . History current , chronic , recurrent infection viral , bacterial , fungal origin describe protocol . Also , subject high risk infection Investigator 's opinion . History lymphoproliferative disorder include lymphoma current sign symptom suggestive lymphoproliferative disease . History malignancy concurrent malignancy describe protocol . Class III IV congestive heart failure History , suspect , demyelinate disease central nervous system ( e.g. , multiple sclerosis optic neuritis ) . Subject condition , Investigator 's judgment , would make subject unsuitable inclusion study . Concurrent medication restriction describe protocol . Subject know tuberculosis ( TB ) infection , high risk acquire TB infection , untreated latent tuberculosis infection ( LTBI ) current history nontuberculous mycobacterial ( NTMB ) infection . Subject protocol define clinically significant laboratory abnormality screen Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>PSO</keyword>
	<keyword>Chronic plaque psoriasis</keyword>
	<keyword>Certolizumb Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Generalized pustular psoriasis erythrodermic psoriasis</keyword>
</DOC>